These observations indicate that the suppression of HDAC6 is an effective and novel therapeutic approach for glioblastoma treatment and overcoming resistance to EGFR inhibitors such as temozolomide [146,150,151]. This evidence concerns the gene HDAC6 and glioblastoma.